Overview

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
0
Participant gender:
All
Summary
This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Revance Therapeutics, Inc.
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA
Criteria
Inclusion Criteria:

- Moderate to severe crow's feet lines

- Female or male, 18 to 65 years of age and in good general health

- Women of childbearing potential (WOCBP) must agree to use an effective method of birth
control during the course of the study

Exclusion Criteria:

- Any neurological condition that may place the subject at increased risk with exposure
to Botulinum Toxin Type A

- Muscle weakness or paralysis, particularly in the area receiving study treatment

- Active skin disease or irritation at the treatment area

- Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated
by manually spreading the skin apart

- Treatment with Botulinum Toxin Type A for crow's feet lines in the last 6 months or 3
months anywhere in the body